Postpartum Depression in Practice - From Universal Screening to Individualized Treatment Within OB/GYN Settings
Postpartum depression (PPD) affects up to one in seven women and is a leading cause of maternal morbidity, with profound implications for both the patient and her family. Untreated PPD can lead to chronic depression, impaired maternal-infant bonding, strained partner relationships, and long-term developmental challenges for the child. These effects are magnified when symptoms go unrecognized or untreated. Early and routine screening, integrated into obstetric and pediatric care, is essential to identify women at risk and initiate timely intervention. Collaborative care models where primary care or OB providers partner with behavioral health care managers and consulting psychiatrists offer a scalable, evidence-based approach to managing PPD. These models improve access to treatment, ensure close follow-up, and have demonstrated superior outcomes compared to standard care.
Precision in Practice: Individualizing MS Therapy Across the Patient Lifespan
The landscape of multiple sclerosis (MS) management is rapidly evolving, requiring community-based neurology clinicians to navigate complex paradigms, from the central role of B-cells in disease progression to the subtle emergence of progression independent of relapse activity (PIRA). With an expanding array of high-efficacy disease-modifying therapies (DMTs), including anti-CD20 monoclonal antibodies and investigational BTK inhibitors, clinicians face intricate decisions regarding patient selection, long-term safety, and individualizing treatment across diverse life stages. This immersive, peer-based digital learning experience brings together small groups of multidisciplinary neurology professionals to collaboratively review and optimize MS care. Guided by regional experts, participants will translate contemporary immunopathogenesis into clinical practice, refine progression monitoring protocols, and develop actionable, personalized strategies to improve long-term patient outcomes.
Raising the Standard for Myasthenia Gravis Care
This interactive program equips neurology providers with practical strategies to improve care for patients with myasthenia gravis. Grounded in real-world clinical challenges, the content focuses on early identification of high-risk patients, individualized treatment planning, and effective integration of newly approved and emerging therapies. Participants will gain insights that can be immediately applied to enhance outcomes across the spectrum of myasthenia gravis severity.
Reducing the Burden of Idiopathic Hypersomnia: Diagnostic and Treatment Considerations
This online program on idiopathic hypersomnia provides healthcare professionals with an in-depth understanding of this complex sleep disorder, including its pathophysiology, diagnosis, and management strategies. Through expert-led presentations and case-based discussions, participants will gain practical insights to improve patient outcomes in clinical practice.
Specialty Specific Guidance: A Cardiologist’s Guide to Using GLP-1 Receptor Agonists in Patients who are Obese
Patients who are obese or overweight are frequently seen in cardiology for other conditions and weight reduction with GLP-1 RAs can be a useful tool in the cardiologist’s toolbox. Through this program, cardiologists will become more familiar with the data supporting the use of GLP 1 RAs in their patients, identify appropriate patients and potential barriers to adherence, and learn how they can more effectively utilize these therapies in their unique patient population.<br> <img src="https://s3.us-east-1.amazonaws.com/media.gathered.com/author/einstein/obm-logo.png" width=170 alt="Obesity Medicine Association Logo" title="Obesity Medicine Association Logo">
Specialty Specific Guidance: An Endocrinologist’s Guide to Using GLP-1 Receptor Agonists in Patients Living with Obesity or Overweight to Help Optimize Their Metabolic Health
Patients who are living with obesity or overweight may seek care with an endocrinologist for other comorbidities, some of which may be directly linked to their weight. Weight reduction and management using pharmacotherapy, including GLP-1 RAs, can be a useful strategy to help patients improve not only their weight but also their metabolic health. Through this program, endocrinologists will gain a deeper understanding of how they can appropriately select patients who may benefit from GLP-1 RAs, especially if they have other comorbidities, and apply clinical trial findings to everyday patient care. They will also enhance their understanding of strategies which can improve both patient adherence and payor authorization/approval.<br> <img src="https://s3.us-east-1.amazonaws.com/media.gathered.com/author/einstein/obm-logo.png" width=170 alt="Obesity Medicine Association Logo" title="Obesity Medicine Association Logo">
Specialty Specific Guidance: An OB/GYN Professionals Guide to Using GLP-1 Receptor Agonists in Patients with Overweight or Obesity to Optimize Women’s Health Across the Lifespan
Women frequently rely on their OB/GYN as their primary source of healthcare, particularly during their reproductive years. Many of these individuals may be living with overweight or obesity, placing the OB/GYN in a uniquely positioned and trusted role to support healthy weight management and broader metabolic health goals. Pharmacotherapy—including GLP-1 receptor agonists—can be an important tool within a comprehensive, patient-centered approach. Through this program, OB/GYNs will develop a deeper understanding of how to appropriately identify candidates for GLP-1 RA therapy across different stages of the lifespan and will learn strategies to improve patient access, streamline documentation, and optimize payor authorization and approval.<br> <img src="https://s3.us-east-1.amazonaws.com/media.gathered.com/author/einstein/obm-logo.png" width=170 alt="Obesity Medicine Association Logo" title="Obesity Medicine Association Logo">
Specialty Specific Guidance: An Orthopedic Surgeon's Guide to Using GLP-1 Receptor Agonists in Patients who are Obese or Overweight to Optimize Joint Health and Surgical Outcomes
Patients who are obese or overweight are more likely to require joint replacement surgery than their normal weight peers; however, higher BMIs also substantially increase the risks of orthopedic surgery. This increased risk often leads to orthopedic surgeons requiring that their patients lose weight and obtain a BMI of <40 kg/m2 before proceeding with surgery. In previous years, bariatric surgery may have been the only feasible option for these patients, but now anti-obesity medications, like GLP-1 receptor agonists, are a valid alternative and may be more palatable for patients. Through this program, orthopedic surgeons will gain a deeper understanding of how they can appropriately select patients who may benefit from GLP-1 RAs and enhance their understanding of strategies which can improve patient access and adherence.<br> <img src="https://s3.us-east-1.amazonaws.com/media.gathered.com/author/einstein/obm-logo.png" width=170 alt="Obesity Medicine Association Logo" title="Obesity Medicine Association Logo">
The Evolving Landscape of GEP-NETs - From Precise Staging to Novel Treatments and Coordinated Care
Welcome to this curriculum on the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This program is designed to provide you with the latest strategies for accurately diagnosing, staging, and treating GEP-NETs by integrating pathological grading with advanced imaging and novel systemic therapies. This activity emphasizes a collaborative approach, encouraging multidisciplinary care coordination to personalize treatment plans and optimize outcomes for patients with this complex disease.
